Actively Recruiting
Study of Maintenance Electroconvulsive Therapy Alongside Clozapine in Treatment-Resistant Schizophrenia Patients Who Respond to Initial ECT
Led by Central Institute of Mental Health, Mannheim · Updated on 2026-02-03
140
Participants Needed
14
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Schizophrenia is a severe mental disorder with significant human and societal costs. Approximately 15-30% of patients do not respond to all known antipsychotic treatments, including clozapine, which is considered the current gold-standard for treatment-resistant cases. This trial aims to evaluate whether adding maintenance electroconvulsive therapy mECT to clozapine treatment improves outcomes for patients who have already responded to an initial course of routine ECT. The goal is to determine if mECT can delay relapse or increase the number of relapse-free patients compared to clozapine treatment alone in clozapine-resistant schizophrenia CRS.
CONDITIONS
Brief Title
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
Research Team
A
Alexander Sartorius, Prof
C
Christian R Wolf, Prof
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
